Patents Assigned to The Trustees of the University of Pennsylvania
  • Patent number: 11607125
    Abstract: A method for non-invasive assessment of photoreceptor function in a mammalian subject comprises exposing a subject's eye to a visible light stimulus to initiate an intrinsic reflectance response in one or a population of photoreceptors and capturing multiple images of photoreceptor's intrinsic reflectance response to the stimulus. Patterns of variability in the intrinsic reflectance response of a single photoreceptor or population of photoreceptors are useful in diagnosis and treatment monitoring of an ocular condition, disease, disorder or a response to treatment for said ocular condition, disease or disorder.
    Type: Grant
    Filed: April 20, 2019
    Date of Patent: March 21, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jessica I. W. Morgan, David H. Brainard, Robert F. Cooper, William S. Tuten
  • Patent number: 11609159
    Abstract: The present subject matter relates to systems, devices, and methods for agricultural sample collection. In one aspect, a sample collection system includes an aerial robotic platform, an arm assembly coupled to the aerial robotic platform and comprising an arm that extends away from the aerial robotic platform, and a sample collector connected to a distal end of the arm, wherein the sample collector is configured to selectively remove one or more samples of agricultural material from a plant to be analyzed.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: March 21, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel Orol, Lukas Vacek, Delaney Vanessa Kaufman, Jnaneshwar Das, R. Vijay Kumar
  • Publication number: 20230076977
    Abstract: The present invention provides methods for increasing expression of utrophin in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a post-transcriptionally utrophin upregulator compound. The present invention also provides methods for treating a subject having a muscular dystrophy. This invention further provides methods for high-throughput screening for a post-transcriptional utrophin upregulator compound.
    Type: Application
    Filed: January 14, 2021
    Publication date: March 9, 2023
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Tejvir S. KHURANA, Donna M. HURYN
  • Publication number: 20230070731
    Abstract: Compositions and methods for small molecule control of precise base editing are disclosed.
    Type: Application
    Filed: January 20, 2021
    Publication date: March 9, 2023
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Rahul Kohli, Junwei Shi, Kiara Berrios
  • Patent number: 11597778
    Abstract: The present invention relates to compositions and methods of use of anti-ADAMTS13 autoantibodies and fragments thereof. In one aspect, the invention includes a composition comprising an isolated anti-ADAMTS13 autoantibody or fragment thereof. In other aspects, methods are described for generating an in vivo model of thrombotic thrombocytopenic purpura (TTP) comprising introducing at least one anti-ADAMTS13 autoantibody or fragment thereof into a model organism and identifying an anti-autoimmune reagent for treating TTP.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 7, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Donald L. Siegel, Stephen Kacir, Eric Ostertag, X. Long Zheng
  • Patent number: 11597911
    Abstract: This invention relates, inter alia, to compositions of low serum or serum free media and methods for the expansion of T cell populations and methods for using such populations of cells. In some aspects, the invention relates to compositions and methods for the selective expansion of T cell subpopulations.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: March 7, 2023
    Assignees: Life Technologies Corporation, The Trustees of the University of Pennsylvania
    Inventors: Angel M. Varela-Rohena, Melanie B. Andolina, James L. Riley, Andrew Medvec
  • Patent number: 11596679
    Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 7, 2023
    Assignees: VANDERBILT UNIVERSITY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE JOHNS HOPKINS UNIVERSITY
    Inventors: James E. Crowe, Jr., Andrew Flyak, Justin Bailey, Stuart Ray, George Shaw
  • Patent number: 11596636
    Abstract: The present invention provides compositions and methods for treating and preventing cancer. The invention comprises an inhibitor of epigenetic regulators, including MLL1, MLL2, MOZ, menin, WDR5, or a combination thereof. In one embodiment, the invention provides a personalized method of treating a cancer as dependent upon its epigenetic signature.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: March 7, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Shelley L. Berger, Xianxin Hua, Morgan Sammons, Jiajun Zhu
  • Patent number: 11597754
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 7, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, John Scholler, Avery D. Posey, Jr.
  • Patent number: 11596678
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 7, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomv and Biologv
    Inventors: David Weiner, Ami Patel, Sarah Elliott
  • Patent number: 11591404
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: February 28, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Patent number: 11591614
    Abstract: Provided herein are methods and compositions for treatment of Batten disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5? inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3? ITR.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 28, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Nathan Katz, Christian Hinderer, Juliette Hordeaux
  • Patent number: 11591298
    Abstract: The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent represent additional aspects of the invention. Methods of treating disease states and/or conditions in which inhibition of autophagy plays a favorable treatment role including rheumatoid arthritis, malaria, antiphospholipid antibody syndrome, lupus, chronic urticaria and Sjogren's disease, with compounds according to the present invention represent additional aspects of the invention.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: February 28, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ravi K. Amaravadi, Jeffrey Winkler
  • Patent number: 11584937
    Abstract: The invention relates to molecules for controlling plant growth and development. Specifically, the invention relates to molecules comprising a gibberellin activator or a gibberellin inhibitor operably linked to a promoter specific to a lateral organ primordium. The invention also relates to transgenic plants having the transgenic molecules and methods for making such transgenic plants.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: February 21, 2023
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Doris Wagner, Nobutoshi Yamaguchi
  • Publication number: 20230046047
    Abstract: The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.
    Type: Application
    Filed: August 25, 2021
    Publication date: February 16, 2023
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Andrew Tsourkas, James Z. Hui
  • Patent number: 11578341
    Abstract: A rAAV vector is described herein which has an AAVhu68 capsid and at least one expression cassette in the capsid. The at least one expression cassette comprises nucleic acid sequences encoding a functional SMN protein and expression control sequences that direct expression of the SMN sequences in a host cell. Also provided are compositions containing this rAAVhu68.SMN vector and methods of using same for spinal muscular atrophy in a patient.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 14, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Christian Hinderer, Nathan Katz, Qiang Wang
  • Patent number: 11581501
    Abstract: An electronic device and a production method thereof, wherein the electronic device includes: a semiconductor layer comprising a plurality of quantum dots; and a first electrode and a second electrode spaced apart from each other; wherein the plurality of quantum dots do not comprise cadmium, lead, or mercury; wherein the plurality of quantum dots comprise indium and optionally gallium; a Group VA element, wherein the Group VA element comprises antimony, arsenic, or a combination thereof, and a molar ratio of the Group VA element with respect to the Group IIIA metal (e.g., indium) is less than or equal to about 1.2:1, and wherein the semiconductor layer may be disposed between the first electrode and the second electrode.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: February 14, 2023
    Assignees: SAMSUNG ELECTRONICS CO., LTD., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Tae Gon Kim, Tianshuo Zhao, Nuri Oh, Cherie Kagan, Eun Joo Jang, Christopher Murray
  • Patent number: 11578137
    Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: February 14, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wenchao Song, Sayaka Sato, Takashi Miwa, Damodar Gullipalli
  • Patent number: 11578130
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 14, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • Patent number: 11578113
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: February 14, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone